JP4533139B2 - アルドステロン介在性病状の処置用剤としての有機化合物 - Google Patents
アルドステロン介在性病状の処置用剤としての有機化合物 Download PDFInfo
- Publication number
- JP4533139B2 JP4533139B2 JP2004526900A JP2004526900A JP4533139B2 JP 4533139 B2 JP4533139 B2 JP 4533139B2 JP 2004526900 A JP2004526900 A JP 2004526900A JP 2004526900 A JP2004526900 A JP 2004526900A JP 4533139 B2 JP4533139 B2 JP 4533139B2
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- pyrazin
- phenyl
- dihydro
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(*)(N)[n]1c(N)c(*)nc1* Chemical compound *C(*)(N)[n]1c(N)c(*)nc1* 0.000 description 2
- BQZVGLJZGCOXHP-UHFFFAOYSA-N CC(C)N(Cc1cnc[n]1C1c(cc2)ccc2C#N)C1=O Chemical compound CC(C)N(Cc1cnc[n]1C1c(cc2)ccc2C#N)C1=O BQZVGLJZGCOXHP-UHFFFAOYSA-N 0.000 description 1
- XBQGXUALPAFHIM-UHFFFAOYSA-N CN(Cc1cnc[n]1C1c2ccccc2)C1=O Chemical compound CN(Cc1cnc[n]1C1c2ccccc2)C1=O XBQGXUALPAFHIM-UHFFFAOYSA-N 0.000 description 1
- VGGBGEMTNNWEPE-UHFFFAOYSA-N COc(cc1)ccc1N(Cc1cnc[n]1C1c(cc2)ccc2Br)C1=O Chemical compound COc(cc1)ccc1N(Cc1cnc[n]1C1c(cc2)ccc2Br)C1=O VGGBGEMTNNWEPE-UHFFFAOYSA-N 0.000 description 1
- GGNMFIOEXAYJBB-UHFFFAOYSA-N COc1ccc(CCN(Cc2cnc[n]2C2c3cccc(Br)c3)C2=O)cc1 Chemical compound COc1ccc(CCN(Cc2cnc[n]2C2c3cccc(Br)c3)C2=O)cc1 GGNMFIOEXAYJBB-UHFFFAOYSA-N 0.000 description 1
- JNSHAFSIADREGA-UHFFFAOYSA-N COc1ccc(CN(Cc2cnc[n]2C2c(cc3)ccc3Br)C2=O)cc1 Chemical compound COc1ccc(CN(Cc2cnc[n]2C2c(cc3)ccc3Br)C2=O)cc1 JNSHAFSIADREGA-UHFFFAOYSA-N 0.000 description 1
- APKLLSXECGEEDD-UHFFFAOYSA-N Cc1ccc(CN(Cc2cnc[n]2C2c3cccc(Br)c3)C2=O)cc1 Chemical compound Cc1ccc(CN(Cc2cnc[n]2C2c3cccc(Br)c3)C2=O)cc1 APKLLSXECGEEDD-UHFFFAOYSA-N 0.000 description 1
- HMACKOWEQJLSOU-UHFFFAOYSA-N O=C1N(Cc2cc(C(F)(F)F)ccc2)Cc2cnc[n]2C1c1cccc(Br)c1 Chemical compound O=C1N(Cc2cc(C(F)(F)F)ccc2)Cc2cnc[n]2C1c1cccc(Br)c1 HMACKOWEQJLSOU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40169302P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008720 WO2004014914A1 (en) | 2002-08-07 | 2003-08-06 | Organic compounds as agents for the treatment of aldosterone mediated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505520A JP2006505520A (ja) | 2006-02-16 |
| JP2006505520A5 JP2006505520A5 (cg-RX-API-DMAC7.html) | 2006-09-21 |
| JP4533139B2 true JP4533139B2 (ja) | 2010-09-01 |
Family
ID=31715720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526900A Expired - Fee Related JP4533139B2 (ja) | 2002-08-07 | 2003-08-06 | アルドステロン介在性病状の処置用剤としての有機化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7732603B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1537114B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4533139B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100404535C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE335744T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003253387A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0313293A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2494636A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1106217T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60307483T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1537114T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2270143T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1537114E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004014914A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612088B2 (en) * | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| AR049711A1 (es) * | 2004-07-09 | 2006-08-30 | Speedel Experimenta Ag | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso |
| TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200813071A (en) * | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| WO2007139992A2 (en) * | 2006-05-26 | 2007-12-06 | Novartis Ag | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS |
| WO2008027284A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| AU2007337659A1 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| US8859538B2 (en) * | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| KR20110036069A (ko) * | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물 |
| CA2763565A1 (en) | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| PL2435409T3 (pl) | 2009-05-28 | 2015-01-30 | Novartis Ag | Podstawione pochodne aminopropionowe jako inhibitory neprylizyny |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| CN103648495A (zh) | 2011-07-08 | 2014-03-19 | 诺华股份有限公司 | 在高甘油三酯对象中治疗动脉粥样硬化的方法 |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| SG11201506018PA (en) | 2013-02-14 | 2015-08-28 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| JP6469214B2 (ja) | 2014-09-25 | 2019-02-13 | オゲダ エス.エー. | N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成 |
| SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CA3095367A1 (en) | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) * | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド |
| JP7777131B2 (ja) | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| KR20230080441A (ko) | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사 활성화 단백질의 이미다조피페라진 억제제 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| IL324432A (en) | 2023-05-24 | 2026-01-01 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
| CN121045094A (zh) * | 2025-04-17 | 2025-12-02 | 成都地奥制药集团有限公司 | 氘代的1,2,4-三嗪化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3582315A (en) * | 1968-03-22 | 1971-06-01 | Lilly Co Eli | Methods and compositions for inhibiting plant growth |
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US6150347A (en) * | 1992-04-21 | 2000-11-21 | The Curators Of The University Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| DE4237656A1 (de) * | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| JPH07101959A (ja) * | 1993-09-30 | 1995-04-18 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体 |
| DE4341453A1 (de) * | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
| AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| US20050014939A1 (en) * | 1999-08-31 | 2005-01-20 | Neurogen Corporation | Fused pyrrolecarboxamides: GABA brain receptor ligands |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
-
2003
- 2003-08-06 ES ES03784194T patent/ES2270143T3/es not_active Expired - Lifetime
- 2003-08-06 WO PCT/EP2003/008720 patent/WO2004014914A1/en not_active Ceased
- 2003-08-06 PT PT03784194T patent/PT1537114E/pt unknown
- 2003-08-06 EP EP03784194A patent/EP1537114B8/en not_active Expired - Lifetime
- 2003-08-06 CA CA002494636A patent/CA2494636A1/en not_active Abandoned
- 2003-08-06 DE DE60307483T patent/DE60307483T2/de not_active Expired - Lifetime
- 2003-08-06 BR BR0313293-5A patent/BR0313293A/pt not_active IP Right Cessation
- 2003-08-06 US US10/523,870 patent/US7732603B2/en not_active Expired - Fee Related
- 2003-08-06 AT AT03784194T patent/ATE335744T1/de not_active IP Right Cessation
- 2003-08-06 AU AU2003253387A patent/AU2003253387A1/en not_active Abandoned
- 2003-08-06 DK DK03784194T patent/DK1537114T3/da active
- 2003-08-06 JP JP2004526900A patent/JP4533139B2/ja not_active Expired - Fee Related
- 2003-08-06 CN CNB038238780A patent/CN100404535C/zh not_active Expired - Lifetime
-
2006
- 2006-10-24 CY CY20061101527T patent/CY1106217T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1537114T3 (da) | 2006-11-13 |
| EP1537114B1 (en) | 2006-08-09 |
| CN1688583A (zh) | 2005-10-26 |
| CY1106217T1 (el) | 2011-06-08 |
| ES2270143T3 (es) | 2007-04-01 |
| EP1537114A1 (en) | 2005-06-08 |
| JP2006505520A (ja) | 2006-02-16 |
| DE60307483T2 (de) | 2007-07-05 |
| ATE335744T1 (de) | 2006-09-15 |
| PT1537114E (pt) | 2006-12-29 |
| WO2004014914A1 (en) | 2004-02-19 |
| HK1080290A1 (en) | 2006-04-21 |
| CN100404535C (zh) | 2008-07-23 |
| DE60307483D1 (de) | 2006-09-21 |
| BR0313293A (pt) | 2005-06-14 |
| US7732603B2 (en) | 2010-06-08 |
| AU2003253387A1 (en) | 2004-02-25 |
| CA2494636A1 (en) | 2004-02-19 |
| EP1537114B8 (en) | 2007-10-03 |
| US20060166973A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1537114B1 (en) | Organic compounds as agents for the treatment of aldosterone mediated conditions | |
| US7223866B2 (en) | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | |
| EP3541390B1 (en) | Pyrrolopyrimidines as cftr potentiators | |
| KR102399206B1 (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| EP2757884B1 (en) | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | |
| KR102268155B1 (ko) | 테트라히드로피라졸로피리미딘 화합물 | |
| JP2006505520A5 (cg-RX-API-DMAC7.html) | ||
| JP2012051807A (ja) | アリールイミダゾール化合物 | |
| KR102540872B1 (ko) | 나프티리디논 유도체 및 부정맥의 치료에서의 이들의 용도 | |
| EP3704106A1 (en) | Alkene compounds as farnesoid x receptor modulators | |
| CN101421279A (zh) | 咪唑化合物 | |
| KR20140040710A (ko) | 아다만틸 화합물 | |
| EP3704107A1 (en) | Multicyclic compounds as farnesoid x receptor modulators | |
| EP2903615B1 (en) | 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension | |
| CA3080893A1 (en) | Alkene spirocyclic compounds as farnesoid x receptor modulators | |
| CN102471319B (zh) | Jnk的抑制剂 | |
| KR100750028B1 (ko) | 치료에 유용한 트리아졸 화합물 | |
| HK1080290B (en) | Organic compounds as agents for the treatment of aldosterone mediated conditions | |
| JP7231610B2 (ja) | インドール誘導体及びその使用 | |
| HK1081540B (en) | Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060802 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100608 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100611 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130618 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |